Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production

Mohan Shenoy, Bruce MacPherson, Premkumar Christadoss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

New compounds with a greater potency than cyclosporin A (CyA) for thwarting host rejection of organ transplantation are being sought. Suramin sodium may be a novel drug to prevent or delay graft rejection and graft-vs-host disease (GVHD), because of its in vitro and in vivo immunosuppressive properties. Since the allogeneic mixed lymphocyte reaction (MLR) is considered to be the in vitro counterpart of the initial T-lymphocyte recognition and response to allogeneic histocompatibility antigens on grafted tissue or organ and to GVHD, we initially evaluated the in vitro suppressive effect of suramin in the allogeneic MLR. Suramin inhibited the H-2- and HLA-incompatible MLR in a dose-dependent manner. The suppressive effect was observed both in the primary and in the secondary MLR. The suppression of the MLR by suramin is due predominantly to the inhibition of interleukin-2 (IL-2) production by the responding T cells.

Original languageEnglish (US)
Pages (from-to)122-129
Number of pages8
JournalJournal of Clinical Immunology
Volume12
Issue number2
DOIs
StatePublished - Mar 1992

Fingerprint

Suramin
Mixed Lymphocyte Culture Test
Lymphokines
Graft vs Host Disease
T-Lymphocytes
Histocompatibility Antigens
Graft Rejection
Organ Transplantation
Immunosuppressive Agents
Cyclosporine
Interleukin-2
Transplants
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • immunosuppression
  • lymphokine production
  • mixed lymphocyte reaction
  • suramin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production. / Shenoy, Mohan; MacPherson, Bruce; Christadoss, Premkumar.

In: Journal of Clinical Immunology, Vol. 12, No. 2, 03.1992, p. 122-129.

Research output: Contribution to journalArticle

Shenoy, Mohan ; MacPherson, Bruce ; Christadoss, Premkumar. / Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production. In: Journal of Clinical Immunology. 1992 ; Vol. 12, No. 2. pp. 122-129.
@article{c62fb0d1e3e14ce8a6a07794c9dbeb9c,
title = "Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production",
abstract = "New compounds with a greater potency than cyclosporin A (CyA) for thwarting host rejection of organ transplantation are being sought. Suramin sodium may be a novel drug to prevent or delay graft rejection and graft-vs-host disease (GVHD), because of its in vitro and in vivo immunosuppressive properties. Since the allogeneic mixed lymphocyte reaction (MLR) is considered to be the in vitro counterpart of the initial T-lymphocyte recognition and response to allogeneic histocompatibility antigens on grafted tissue or organ and to GVHD, we initially evaluated the in vitro suppressive effect of suramin in the allogeneic MLR. Suramin inhibited the H-2- and HLA-incompatible MLR in a dose-dependent manner. The suppressive effect was observed both in the primary and in the secondary MLR. The suppression of the MLR by suramin is due predominantly to the inhibition of interleukin-2 (IL-2) production by the responding T cells.",
keywords = "immunosuppression, lymphokine production, mixed lymphocyte reaction, suramin",
author = "Mohan Shenoy and Bruce MacPherson and Premkumar Christadoss",
year = "1992",
month = "3",
doi = "10.1007/BF00918142",
language = "English (US)",
volume = "12",
pages = "122--129",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production

AU - Shenoy, Mohan

AU - MacPherson, Bruce

AU - Christadoss, Premkumar

PY - 1992/3

Y1 - 1992/3

N2 - New compounds with a greater potency than cyclosporin A (CyA) for thwarting host rejection of organ transplantation are being sought. Suramin sodium may be a novel drug to prevent or delay graft rejection and graft-vs-host disease (GVHD), because of its in vitro and in vivo immunosuppressive properties. Since the allogeneic mixed lymphocyte reaction (MLR) is considered to be the in vitro counterpart of the initial T-lymphocyte recognition and response to allogeneic histocompatibility antigens on grafted tissue or organ and to GVHD, we initially evaluated the in vitro suppressive effect of suramin in the allogeneic MLR. Suramin inhibited the H-2- and HLA-incompatible MLR in a dose-dependent manner. The suppressive effect was observed both in the primary and in the secondary MLR. The suppression of the MLR by suramin is due predominantly to the inhibition of interleukin-2 (IL-2) production by the responding T cells.

AB - New compounds with a greater potency than cyclosporin A (CyA) for thwarting host rejection of organ transplantation are being sought. Suramin sodium may be a novel drug to prevent or delay graft rejection and graft-vs-host disease (GVHD), because of its in vitro and in vivo immunosuppressive properties. Since the allogeneic mixed lymphocyte reaction (MLR) is considered to be the in vitro counterpart of the initial T-lymphocyte recognition and response to allogeneic histocompatibility antigens on grafted tissue or organ and to GVHD, we initially evaluated the in vitro suppressive effect of suramin in the allogeneic MLR. Suramin inhibited the H-2- and HLA-incompatible MLR in a dose-dependent manner. The suppressive effect was observed both in the primary and in the secondary MLR. The suppression of the MLR by suramin is due predominantly to the inhibition of interleukin-2 (IL-2) production by the responding T cells.

KW - immunosuppression

KW - lymphokine production

KW - mixed lymphocyte reaction

KW - suramin

UR - http://www.scopus.com/inward/record.url?scp=0026519024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026519024&partnerID=8YFLogxK

U2 - 10.1007/BF00918142

DO - 10.1007/BF00918142

M3 - Article

C2 - 1532803

AN - SCOPUS:0026519024

VL - 12

SP - 122

EP - 129

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 2

ER -